A PYMNTS Company

US: Momenta, Amphastar settle generic drug patent case

 |  June 20, 2019

OnWednesday, Amphastar Pharmaceuticals said Momenta Pharmaceuticals Inc and Novartis AG’s Sandoz unit will pay it $59.9 million to resolve patent and antitrust lawsuits over their dueling generic versions of the blood-thinner Lovenox.

The settlement ends an appeal by Momenta and Sandoz of a Boston federal jury’s 2017 verdict finding that a patent they claimed Amphastar infringed was invalid, a decision that exposed them to losing $100 million that they had posted as a bond earlier in the litigation.

Full Content: Reuters

Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.